Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa
Year: 2025
Type: article
Abstract: PsoriasisDear editors, Palmoplantar pustulosis (PPP) is a chronic, relapsing inflammatory skin disease characterized by sterile pustules, erythema, and hyperkeratosis on the palms and/or soles.It causes pain and itching, and can impair quality of life.1,2 The treatment of PPP is challenging, and standardized treatment guidelines are lacking.Bimekizumab, a dual inhibitor of interleukin (IL)-17A and IL-17F, is approved for treating plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa (HS).3 It has also emerged as a promising therapeutic option for PPP. 4 Here, we present a case study of a patient with severe PPP and HS who was successfully treated with bimekizumab combined with topical phototherapy with psoralen plus ultraviolet A (PUVA).A 62-year-old Caucasian woman presented with HS and PPP.The HS had manifested ten years earlier and had been treated surgically twice, and showed an insufficient response to six months systemic therapy with clindamycin and rifampicin (600 mg each per day).The patient presented with Hurley stage 2 HS in the inguinal and genital region.Itchy, sharply defined erythematosquamous plaques and pustules were present on her palms and soles that had appeared six months earlier (Figure 1a), prior to the initiation of any systemic therapy for HS.Neither plaque psoriasis nor joint pain were present.There was no family history of skin diseases.She was a current smoker with a 15-pack-year history.Her BMI was 30.5, and her other comorbidities were arterial hypertension, a C7/8
DOI: 10.1111/ddg.15986
Institutions: Universitätsmedizin Göttingen, University of Göttingen
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,480
OpenAlex ID: W4415313582